• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.

作者信息

Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T

机构信息

Department of Infectious Diseases, Nagoya University School of Medicine, Japan.

出版信息

Leukemia. 1998 Sep;12(9):1333-7. doi: 10.1038/sj.leu.2401130.

DOI:10.1038/sj.leu.2401130
PMID:9737679
Abstract

An internal tandem duplication (ITD) of the FLT3 gene is found in nearly 20% of acute myeloid leukemia (AML) and 5% of myelodysplastic syndrome cases. Our serial studies on 51 samples with the FLT3 gene mutation indicated that the ITD was frequently (47/51) clustered in the tyrosine-rich stretch from codon 589 to 599 and rarely (3/51) in its downstream region, both of which are located within the juxtamembrane (JM) domain. One remaining sample had an insertion into the JM domain of nucleotides of unknown origin. To elucidate the biological relevance of the ITD or the insertion, we expressed various types of mutant FLT3 in Cos 7 cells. All mutant FLT3 studied were ligand-independently dimerized and their tyrosine residues were phosphorylated. The Y589 of FLT3 was essential for the phosphorylation in the wild FLT3, but a Y589F conversion did not affect the phosphorylation status of the mutant FLT3. These findings suggest that the elongation of the JM domain rather than increase of tyrosine residues causes gain-of-function of FLT3. Thus, ITD is a novel modality of somatic mutation which activates its product. Since the DNA corresponding to codon 593 to 602 potentially forms a palindromic intermediate, we propose that a DNA-replication error might be associated with generating the ITD of the FLT3 gene.

摘要

相似文献

1
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
Leukemia. 1998 Sep;12(9):1333-7. doi: 10.1038/sj.leu.2401130.
2
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.人类血液系统恶性肿瘤中FLT3激活环内D835的激活突变。
Blood. 2001 Apr 15;97(8):2434-9. doi: 10.1182/blood.v97.8.2434.
3
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.利用外周血血浆DNA更好地检测FLT3内部串联重复。
Leukemia. 2003 Jan;17(1):114-9. doi: 10.1038/sj.leu.2402743.
4
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.近膜结构域中存在内部串联重复的FLT3组成性激活机制。
Oncogene. 2002 Apr 11;21(16):2555-63. doi: 10.1038/sj.onc.1205332.
5
FLT3 mutations in acute myeloid leukemia cell lines.急性髓系白血病细胞系中的FLT3突变
Leukemia. 2003 Jan;17(1):120-4. doi: 10.1038/sj.leu.2402740.
6
Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.FMS样酪氨酸激酶3的内部串联重复与骨髓增生异常综合征患者的不良预后相关。
Cancer. 2004 Sep 1;101(5):989-98. doi: 10.1002/cncr.20440.
7
FLT3/ITD mutation signaling includes suppression of SHP-1.FLT3/ITD突变信号传导包括对SHP-1的抑制。
J Biol Chem. 2005 Feb 18;280(7):5361-9. doi: 10.1074/jbc.M411974200. Epub 2004 Dec 1.
8
Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.FLT3基因的内部串联重复在各种血液系统恶性肿瘤中,在急性髓系白血病和骨髓增生异常综合征中更为常见。一项针对大量患者和细胞系的研究。
Leukemia. 1997 Oct;11(10):1605-9. doi: 10.1038/sj.leu.2400812.
9
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.对酪氨酸激酶抑制剂的敏感性在FLT3受体的不同激活突变之间存在差异。
Blood. 2003 Jul 15;102(2):646-51. doi: 10.1182/blood-2002-11-3441. Epub 2003 Mar 27.
10
Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.Ki23819的鉴定,一种对突变型FLT3受体酪氨酸激酶的激酶活性具有高效抑制作用的物质。
Leukemia. 2005 Jun;19(6):930-5. doi: 10.1038/sj.leu.2403736.

引用本文的文献

1
Clinical profile of -ITD mutation in West Algerian population with acute myeloid leukemia.阿尔及利亚西部急性髓系白血病患者中-ITD突变的临床特征
Mol Biol Res Commun. 2024;13(3):175-182. doi: 10.22099/mbrc.2024.49437.1955.
2
Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.白血病突变 FLT3-ITD 保留在树突状细胞中,并破坏其稳态,导致 Th17 频率增加。
Front Immunol. 2024 Mar 1;15:1297338. doi: 10.3389/fimmu.2024.1297338. eCollection 2024.
3
Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements.
将靶向RNA测序面板的临床应用从基因融合扩展到复杂的基因内结构重排。
Cancers (Basel). 2023 Sep 2;15(17):4394. doi: 10.3390/cancers15174394.
4
Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.携带FLT3-ITD突变的急性髓系白血病患者中N-MYC癌基因表达的变化
Pathophysiology. 2023 Aug 1;30(3):296-313. doi: 10.3390/pathophysiology30030024.
5
FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile.FMS样酪氨酸激酶3抑制剂治疗急性髓系白血病:新证据及安全性概况的最新进展
Onco Targets Ther. 2023 Jan 19;16:31-45. doi: 10.2147/OTT.S236740. eCollection 2023.
6
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8 T cells.BET 抑制剂通过增强白血病来源的终末耗竭 CD8 T 细胞中的 TCF7 可及性来挽救抗 PD-1 耐药性。
Leukemia. 2023 Mar;37(3):580-592. doi: 10.1038/s41375-023-01808-0. Epub 2023 Jan 21.
7
ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.ACC010,一种新型的 BRD4 抑制剂,与高三尖杉酯碱在伴有 FLT3-ITD 的急性髓系白血病中具有协同作用。
Mol Oncol. 2023 Jul;17(7):1402-1418. doi: 10.1002/1878-0261.13368. Epub 2023 Jan 21.
8
Evaluation of Mutations and Gene Expression in AML Patients.急性髓系白血病患者的突变与基因表达评估
Iran J Pathol. 2022 Fall;17(4):419-426. doi: 10.30699/IJP.2022.543485.2776. Epub 2022 Sep 20.
9
Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.在接受异基因外周血造血干细胞移植的复发/难治性急性髓系白血病患者中,成功地进行了吉特替尼的移植前和移植后治疗。
Intern Med. 2023 Aug 1;62(15):2243-2247. doi: 10.2169/internalmedicine.1069-22. Epub 2022 Nov 30.
10
Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.FLT3 抑制剂在急性髓系白血病患者中的临床疗效。
Int J Mol Sci. 2022 Oct 21;23(20):12708. doi: 10.3390/ijms232012708.